Diabetes
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Diabetes Home
    • Products
      Diabetes Treatments
    • Professional Resources
      Product Resources Library Insulin & Type 1 Diabetes
    • Professional Training
      Insulin Pen Training
  • Sample Requests
    • Diabetes Education
      Clinical Education Library Diabetes Risk Assessment Tool
    • Treatment Guidelines
      ADA Standards of Care AACE Diabetes Guidelines
    • Additional Resources
      Utilizing Your EHR Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards Insurance Coverage Affordability Resources
    • Support Program
      Diabetes Management
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Medical Information
    Non-US Health Care Professionals
Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL logo
Important Safety Information | Patient Site
Prescribing Information
    • How Does Tresiba® Work?
    • Product Profile
    • Tresiba® and Type 1
    • Hear from Your Peers
    • Frequently Asked Questions
    • Type 2 Efficacy and Safety
    • Type 1 Efficacy and Safety
    • Hypoglycemia Facts
    • DEVOTE Study: MACE and Severe Hypoglycemia
    • SWITCH 2 Study: Hypoglycemia Data
    • Starting Adult Patients
    • Starting Pediatric Patients
    • Dose Timing Guidance
    • Tresiba® FlexTouch® and Vial
  • Cost and Coverage
    • Samples
    • Tresiba® Sample Starts
    • Patient Support
    • For Pharmacists
    • Video Library
Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL logo

Prescribing Information
Important Safety Information | Patient Site

Savings and coverage tools to help your patients start Tresiba® (insulin degludec)

Tresiba® savings card image

Formulary coverage     |     Savings card     |     Affordability offerings

Formulary coverage

Savings card

Affordability offerings

Novo Nordisk has the best formulary coverage in the basal category

Tresiba® has ~87.5% national formulary coverage (commercial and Medicare Part D combined) and is covered nationwide on the majority of Medicare Part D plans.1,a-c Use the formulary tool to check coverage in your area.

Find out exactly which plans in your area include Tresiba®. Formulary status is believed to be accurate at the time of update but cannot be guaranteed.

aFormulary status subject to change. This information should not be used to make efficacy or safety comparisons between or among mentioned products.
bFormulary data are provided by Managed Markets Insight & Technology, LLC (MMIT) and are current as of February 2022.
cMedicare Part D data are on file with Novo Nordisk and are current as of February 2022.

What can patients expect to pay for Tresiba®?

Commercially ins­ured patients

WITHOUT co-pay card

The vast majority of patients pay $35 or less per monthly co-pay2,d

WITH co-pay card

With the Tresiba® Savings Card, eligible patients pay as little as $25 or no more than $99 per prescription.e

Tresiba® is the less expensive option vs most other basal insulins for commercially insured patientsf

Patients can get or activate their savings card at TresibaSavings.com

Medicare Part D patients

WITHOUT assistance

The majority of patients pay $50 or less per monthly co-pay2,d,g

WITH assistance

Low-Income Subsidy or Extra Help patients likely pay $9.85 per month or less3

  • Nearly 50% of Part D Tresiba® patients receive Low-Income Subsidy or Extra Help benefits2
  • Average Medicare co-pays for Tresiba® are comparable with other branded basal insulins2,f

dResults based on average monthly patient out-of-pocket cost for Tresiba® from IQVIA LAAD, January 2021-December 2021. Excludes cash-paying patients.
eEligibility and other restrictions apply. 
fOther branded basal insulins include Basaglar®, Lantus®, Levemir®, Semglee®, and Toujeo®.
gExcludes Low-Income Subsidy or Extra Help Medicare patients.3


My$99Insulin

Eligible patients pay $99 for a monthly supply of any combination of Novo Nordisk insulin products (up to 3 vials or 2 packs of pens)h. Learn more at NovoCare.com.

hSee terms and conditions for details.

Tresiba® (insulin degludec) Co-pay Card
(1:57)

Accessing Tresiba® for a low out-of-pocket cost

The cost your patients will pay can depend on formulary coverage, deductibles, co-pay amounts, or coinsurance. Options for your patients to access Tresiba® at a low cost are explained more in this short video.

Find affordability programs to help patients save on their insulin

See all the insulin affordability offerings at NovoCare.com, including the Novo Nordisk Patient Assistance Program (PAP), which offers Tresiba® at no cost to those who qualify for up to a yeari

iFull patient eligibility requirements can be found at NovoCare.com.

Request samplesj to start patients on Tresiba®

jYou must be a licensed practitioner who can legally prescribe medication in your state. (Request for product samples is limited to 1 request per health care professional.)

Get samples
Request Tresiba® samples

Indications and Usage for Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL

Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba® 
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
    • Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
    • Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
    • Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
    • Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine

 

Please click here for Tresiba® Prescribing Information.

References:

  1. Formulary data are provided by Managed Markets Insight & Technology, LLC (MMIT) and are current as of February 2022. Transaction and claims data are provided by Managed Markets Insight & Technology, LLC (MMIT) for the period February 2022. Medicare Part D cost shares are provided by Managed Markets Insight & Technology, LLC (MMIT), February 2022, and represent the initial coverage period.
  2. IQVIA LAAD, January 2021-December 2021
  3. Centers for Medicare & Medicaid Services. Advance Notice of Methodological Changes for Calendar Year (CY) 2022 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies – Part II. Accessed March 17, 2022. https://www.cms.gov/files/document/lis-memo.pdf. Published October 25, 2021.
Diabetes
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Diabetes Home
  • Product Information
    Products
    • Diabetes Treatments
    Professional Resources
    • Product Resources Library
      Insulin & Type 1 Diabetes
    Professional Training
    • Insulin Pen Training
  • Sample Requests
  • Professional Education
    Diabetes Education
    • Clinical Education Library
      Diabetes Risk Assessment Tool
    Treatment Guidelines
    • ADA Standards of Care
      AACE Diabetes Guidelines
    Additional Resources
    • Utilizing Your EHR
      Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Insurance Coverage
      Affordability Resources
    Support Program
    • Diabetes Management

Cornerstones4Care®, FlexTouch®, Levemir®, NovoFine®, NovoLog®, PenFill®, and Tresiba® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22TSM00024 April 2022

Quick links

Request medication samples

Diabetes treatment guidelines

Patient savings card offer

Patient support program